GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Biomea Fusion BMEA · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.59

+11.02%

Close of 19 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Biomea Fusion — daily BMEA Delayed
Market value
$41.6m
Last close × shares
Volume
951.9k
Shares, 19 Nov 2026

About Biomea Fusion

From its filings with the US Securities and Exchange Commission

SEC filings

Biomea Fusion is based in San Carlos, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker BMEA. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $61.8m. At that date it held total assets of $58.6m and shareholders' equity of $29.6m.

In its own words

We are a clinical‑stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases.

The company was founded in 2017 with the goal of creating targeted treatments built through expertise in chemistry and a deep understanding of metabolic biology. Following the strategic realignment announced in 2025, we now operate as an organization centered on two of our core drug candidate development programs: (i) icovamenib, our lead clinical program’s drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib’s potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, our investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist (GLP-1 RA) in development for the treatment of obesity.

Today, we have approximately 40 employees and a streamlined operating structure that we believe emphasizes capital efficiency, scientific discipline and focused execution. Our research and development functions are supported by integrated clinical development, clinical operations, clinical pharmacology, regulatory affairs, pharmacovigilance and quality functions.

Quoted from its 10-K, filed 24 Mar 2026. Read the filing on SEC.gov ↗

More about Biomea Fusion →

Latest on Biomea Fusion

Our reporting

Next results

23 Mar 2027

Due on 23 Mar 2027. Analysts expect earnings of -0.17 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Biomea Fusion's ticker?

Biomea Fusion trades as BMEA on its US listing, under ISIN US09077A1060.

What was Biomea Fusion's last closing price?

0.59 on 19 Nov 2026. The figure is in USD and is never converted.

When does Biomea Fusion next report results?

Results are expected on 30 Mar 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
SEC filings and our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.